# A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

> **NCT00267007** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 32 (actual)

## Conditions studied

- Peripheral Neuropathy, Chemotherapy-induced

## Interventions

- **DRUG:** PROCRIT 40,000 IU QW
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00267007
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2014-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267007, "A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00267007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*